CTRL Therapeutics, a biotechnology company developing a next-generation cell therapy platform for solid tumors, announced a $10M seed financing led by General Catalyst with participation from Intermountain Health, FACIT and other investors.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
